TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical system firm targeted on the event and commercialization of progressive surgical applied sciences for single entry robotic-assisted surgical procedure (RAS), right now introduced the publication of worldwide patent utility No. PCT/CA2022/050392, which the corporate anticipates pursuing within the United States and different key markets beneath the Patent Cooperation Treaty (PCT).
The patent utility typically discloses dexterous endoscope applied sciences to be used with RAS techniques which are designed to offer a strong workspace area of view higher than these supplied by prior endoscope applied sciences, that are designed to seize solely a portion of a surgical web site. Technology described within the patent utility could possibly be utilized in a range of single entry RAS techniques, together with these designed to assist three devices which are concurrently positionable inside an insertion conduit.
“It was important for us to share the publication of this patent application as it highlights our continued commitment to be an innovation leader in single access RAS, which includes but also extends beyond the current development of the Enos™ surgical system,” stated Cary Vance, President and CEO of Titan. “While we are focused on the development, clinical and regulatory activities for the Enos system, we are committed to continuing to advance the surgical experience for patients, surgeons and hospitals through the research and development of RAS technology components and systems. Filing patent applications on our inventions remains an important step in protecting the value we continue to generate, including those designed for next-generation technologies and systems. As we further innovate and develop our RAS technology roadmap, we expect to extend our leadership in single access innovation and intellectual property, competitively positioning Titan, particularly with respect to upcoming RAS entrants.”
Titan has developed an expansive mental property portfolio with over 220 pending and issued patents protecting the United States and different jurisdictions that assist and canopy varied facets of single-access RAS together with the Enos system’s surgeon workstation, affected person cart, dexterous articulating devices, ergonomic hand-controllers, enhanced imaginative and prescient techniques, superior management software program, and instinctive surgeon overlays for offering interoperative suggestions. This protection of single-access RAS, and specifically the Enos system, together with protection of extra normal facets of RAS applied sciences, could present the corporate with a number of mental property choices together with additional defending its RAS applied sciences, and the potential to additional license its applied sciences and help in securing a aggressive business pathway.
About Titan Medical
Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical system firm headquartered in Toronto, Ontario with operations in Chapel Hill, North Carolina, is targeted on enhancing robotic assisted surgical procedure (RAS) utilizing progressive expertise by means of a single entry level. The Enos™ robotic single entry surgical system is being developed with an ergonomic focus to offer a surgical expertise that imitates real-life actions that surgeons demand and contains multi-articulating devices designed to permit surgeons an elevated vary of movement in a confined area, with dexterity and the power to exert the forces mandatory to finish frequent surgical duties. With the Enos system, Titan intends to initially pursue gynecologic surgical indications.
Enos™ is a trademark of Titan Medical Inc.
For extra data, go to www.titanmedicalinc.com and observe @TitanMedical on Twitter and LinkedIn.
Forward-Looking Statements
This information launch accommodates “forward-looking statements” inside the which means of relevant Canadian and U.S. securities legal guidelines, which replicate the present expectations of administration of the corporate’s future progress, outcomes of operations, efficiency and business prospects and alternatives. Forward-looking statements are incessantly, however not all the time, recognized by phrases equivalent to “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and comparable expressions, though these phrases might not be current in all forward-looking statements. Forward-looking statements that seem on this launch could embrace, with out limitation, references to: the corporate’s plans beneath the PCT; the potential benefits of the corporate’s applied sciences together with dexterous endoscope applied sciences offering a strong workspace area of view; the expertise described within the patent utility being utilized in a range of single entry RAS system; the corporate’s dedication to being an innovation chief in single entry RAS, which incorporates but in addition extends past the Enos system; the corporate’s dedication to advance the surgical expertise for sufferers, surgeons and hospitals; the corporate’s expectation to increase its management in single entry improvements and mental property; the corporate’s aggressive place, together with with respect to approaching RAS entrants; the protection of and the choices supplied by the corporate’s mental property portfolio; the Enos robotic single entry surgical system being developed with an ergonomic focus to offer a surgical expertise that imitates real-life actions that surgeons demand; and that Titan intends to initially pursue gynecologic surgical indications. These statements replicate administration’s present beliefs with respect to future occasions and are based mostly on data at present obtainable to administration. Forward-looking statements contain vital dangers, uncertainties and assumptions. Many components might trigger the corporate’s precise outcomes, efficiency or achievements to be materially totally different from any future outcomes, efficiency or achievements that could be expressed or implied by such forward-looking statements, together with, with out limitation, these listed within the “Risk Factors” part of the corporate’s Annual Report for the fiscal yr ended December 31, 2021 which can be considered at www.sedar.com and at www.sec.gov. Should a number of of these dangers or uncertainties materialize, or ought to assumptions underlying the forward-looking statements show incorrect, precise outcomes, efficiency, or achievements could fluctuate materially from these expressed or implied by the forward-looking statements contained on this information launch. These components must be thought-about fastidiously, and potential buyers mustn’t place undue reliance on the forward-looking statements. Although the forward-looking statements contained within the information launch are based mostly upon what administration at present believes to be affordable assumptions, the corporate can not guarantee potential buyers that precise outcomes, efficiency or achievements might be in step with these forward-looking statements. Except as required by legislation, the corporate expressly disclaims any intention or obligation to replace or revise any forward-looking statements whether or not because of this of new data, future occasions or in any other case.
Contact
Kristen Galfetti
Vice President, Investor Relations
& Corporate Communications
+1-781-869-2553
[email protected]
###
